Clinical Advances in
The treatment of HR-positive breast cancer is undergoing significant changes with the introduction of novel targeted therapies such as cyclin-dependent kinase (CDK) 4 and 6 inhibitors that are already demonstrating improvements in patient outcomes. As different agents become available and are increasingly integrated into treatment algorithms, clinical challenges are created regarding rational treatment selection, appropriate patient selection, and sequencing of treatments.
Supported by an independent educational sponsorship from
The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination With Letrozole Versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1/TRIO-18): A Randomised Phase 2 Study
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
Steering Committee Chair
Centre for Experimental Cancer Medicine
St. Bartholomew Hospital
Chair of Cancer Medicine and Honorary Consultant in Medical Oncology Barts Cancer Institute
Queen Mary University London
London, United Kingdom
Professor, University of Milano; Head, European Institute of Oncology, Milan, Italy
Celebrating Womens Chair in Breast Cancer
Research
Baylor University Medical Center
Texas Oncology
US Oncology
Dallas, Texas, United States
Head, Medical Oncology, CHU Sart Tilman Liège; Professor of Medical Oncology, Liège University, Liège, Belgium
Chair German Breast Group, Sana Kliniken Offenbach, Breast Cancer Center; Associate Professor, University Frankfurt am Main, Frankfurt, Germany